✦ LIBER ✦

T cell depletion with campath I to prevent GVHD after allogeneic bone marrow transplantation

✍ Scribed by G. Bandini; P. Ricci; M. Gobbi; P.L. Tazzari; M.R. Motta; C. Guardigli; M. Baccarani; S. Tura

Book ID: 113238695
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 95 KB
Volume: 10
Category: Article
ISSN: 0145-2126
DOI: 10.1016/0145-2126(86)90218-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

GvHD prophylaxis in allogeneic bone marr

GvHD prophylaxis in allogeneic bone marrow transplantation using t-cell depletion by campath i and complement

✍ M. Wiesneth; R. Arnold; D. Bunjes; B. Hertenstein; Th. Schmeiser; G. Hale; H. He 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 99 KB

T-cell depletion to prevent GVHD after u

T-cell depletion to prevent GVHD after unrelated-donor marrow transplantation

✍ Franco Locatelli; Piero De Stefano 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 47 KB

T-cell depletion versus methotrexate as

T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia

✍ Dr. M. Wiesneth; B. Hertenstein; D. Bunjes; T. Schmeiser; R. Arnold; H. Heimpel; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 436 KB

Quantity and nature of marrow T cells af

Quantity and nature of marrow T cells after their depletion with campath I

✍ C. Irlé; M. Kaestli; M. Aapro; B. Chapuis; M. Jeannet 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Bone Marrow B cell Precursor Number afte

Bone Marrow B cell Precursor Number after Allogeneic Stem Cell Transplantation and GVHD Development

✍ Yuri Fedoriw; T. Danielle Samulski; Allison M. Deal; Cherie H. Dunphy; Andrew Sh 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 393 KB

Adoptive transfer of immunity to hepatit

Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation

✍ Yaron Ilan; Arnon Nagler; Ruth Adler; Elizabeth Naparstek; Reuven Or; Shimon Sla 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

Recipients of allogeneic bone marrow transplantation are pancytopenic for several weeks and immunosuppressed for many months as a result of myeloablative therapy required to eliminate the basic disease and to prevent allograft rejection. After bone marrow transplantation, these patients remain profo